Skip to content

PHARMES BELGIË

Active
Private limited companyfounded 2024active for 2 yearsTumulusstraat 4, 8710 Wielsbeke, BelgiumKBO/BCE: BE 1008.128.324
Summary

The computed 12-month bankruptcy probability of PHARMES BELGIË is 2.5% (moderate). The 2025 annual accounts show equity of €17,978 and a net result of €13,978. Its solvency ranks better than 12% of 34,946 sector peers (NACE 43, financial year 2025). The company has been active since 2024 and the Belgian Official Gazette contains no insolvency or warning signals.

Overview

Official details

Source: KBO
Status
Active since 08-04-2024 Normal situation
Activity
Other construction installation NACE 43240and 3 others
Establishment unit
2.358.127.804 8710 Wielsbeke, since 08-04-2024
Financial year end
31 December
Peppol
Reachable since 04-12-2025

Financial position

50 Fair Checked score 2025
Bankruptcy probabilitywithin 12 months
2.5%
Annual accounts 2025
Gross margin
€66,183
Turnover
≈ €260,000
estimated
Profit
€13,978
Equity
€17,978
Total assets
€291,257
Employees on 31-12-2025
1
Filed on 25-04-2026, 97 days before the deadline
Score breakdownraises riskFounded in 20241 change of registered office in 24 monthsEquity €17,978 (6.2% of total assets)lowers riskFigures for financial year 2025 (filed on 28-04-2026)Show the evidence

Checked score

Score 2025
50 / 100
Fair
Probability in this band: 1.5% to 4.2%
Financially stronger than 23% of micro companies in specialised construction (NACE 43)
Financial strength
Weak
Solvency 31
equity 6.2% of total assets
Liquidity 19
short-term debt 81.8% · cash 11.2%
Profitability 75
return on assets 4.8%
Bankruptcy probability within 12 months
2.5% Moderate
0%0.5%1.5%4%10%≥ 25%

About 3 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.7% (47,674 companies, NACE 43, micro)
Last 24 months 05-2025: 3.8% 06-2025: 3.9%▲ +0.1 percentage points vs 05-2025 07-2025: 4.0%▲ +0.1 percentage points vs 06-2025 08-2025: 4.5%▲ +0.5 percentage points vs 07-2025 09-2025: 4.5%● unchanged vs 08-2025 10-2025: 5.0%▲ +0.5 percentage points vs 09-2025 11-2025: 5.2%▲ +0.2 percentage points vs 10-2025 12-2025: 5.3%▲ +0.1 percentage points vs 11-2025 01-2026: 5.1%▼ -0.2 percentage points vs 12-2025 02-2026: 5.2%▲ +0.1 percentage points vs 01-2026 03-2026: 5.5%▲ +0.3 percentage points vs 02-2026 04-2026: 5.6%▲ +0.1 percentage points vs 03-2026highest value 05-2026: 2.6%▼ -3.0 percentage points vs 04-2026 06-2026: 2.6%● unchanged vs 05-2026 07-2026: 2.6%● unchanged vs 06-2026 08-2026: 2.6%● unchanged vs 07-2026 09-2026: 2.6%● unchanged vs 08-2026 10-2026: 2.5%▼ -0.1 percentage points vs 09-2026lowest value 11-2026: 2.5%● unchanged vs 10-2026lowest value
Credit of up to €500 on 30-day terms is acceptable
Liquidity is insufficient, with a current ratio of 0.72, below 1. Short-term debt is 81.8% and cash 11.2% of total assets. 93.8% of the assets are financed with debt and provisions.
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 43, micro). It does better than 11% of them on solvency, 11% on liquidity and 48% on profitability.

The bankruptcy probability was computed on 01-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Six signals.
lowers riskraises riskneutral
raises risk · Founded in 2024
Companies of this age fail more often than older ones. How much that weighs depends on the rest of the company's profile.
KBO
lowers risk · Figures for financial year 2025 (filed on 28-04-2026)
NBB · annual accounts
raises risk · 1 change of registered office in 24 months
Belgian Official Gazette
raises risk · Equity €17,978 (6.2% of total assets)
NBB · annual accounts
raises risk · Weak solvency compared with the sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 12% of 34946 sector peers (2025).
NBB · sector comparison
Position among 34946 sector peers
Solvency
better than 12%
← weakest strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 25-04-2026, 97 days ahead of the deadline.
NBB · 1 filing
Deviation from the deadline
2025
97 days early
← before the deadline after the deadline →
Searched, nothing found (1)
neutral · No strike-offs in the KBO publications
That holds for every publication since incorporation in 2024.
KBO publications

Key points

  • Caution: Lower solvency than 88% of companies in specialised constructionsector median 46.7% · 34,946 companies 6.2% View

Recent changes

  1. · Gazette deed Registered office moved from Oostrozebeke to Wielsbeke
  2. · Gazette deed IncorporationStarting capital €4,000 · Appointments: DOMBRECHT, Pieter (director) and DEJAGER, Mathieu Raoul Francina (director)
All 3 events

Comparable companies

These companies have the same main activity as PHARMES BELGIË: other construction installation (NACE 43240). They are comparable in size and age: total assets between €264,000 and €381,000, founded between 2023 and 2024.

CompanyTotal assetsGross margin
PHARMES BELGIË Wielsbeke€291,257€66,183
SKE SERVICE Langemark-Poelkapelle€316,489€76,668
Acrobat Construct Linter€263,552€66,866
CJ Zonwering Kortenberg€338,108€74,573
OH MY KEY Chaumont-Gistoux€381,344€67,744
Foliefixx Maaseik€296,850€65,824
THERMOMATTE Wezembeek-Oppem€275,256€98,901
Full comparison

Key facts about PHARMES BELGIË

What is the company number of PHARMES BELGIË?
The company number of PHARMES BELGIË is 1008.128.324. The VAT number is the same number with BE in front: BE 1008.128.324.
Where is PHARMES BELGIË based?
The registered office is at Tumulusstraat 4, 8710 Wielsbeke.Company details
What does PHARMES BELGIË do?
According to the KBO register, the main activity is other construction installation (NACE 43240).
What is the legal form of PHARMES BELGIË?
The legal form of PHARMES BELGIË is Private limited company (BV).
When was PHARMES BELGIË founded?
PHARMES BELGIË was founded on 08-04-2024.
Is PHARMES BELGIË still active?
Yes, PHARMES BELGIË is an active enterprise in the KBO register.
How many employees does PHARMES BELGIË have?
PHARMES BELGIË had an average of 1 full-time equivalents in financial year 2025, according to the filed annual accounts.Financials
What is the turnover of PHARMES BELGIË?
The turnover in financial year 2025 is ≈ €260,000. This figure is estimated from the gross margin of €66,183 and 108 comparable companies (NACE 432). It probably lies between €190,000 and €380,000.
Is PHARMES BELGIË profitable?
In financial year 2025, PHARMES BELGIË made a profit of €13,978.
Where can I find the annual accounts of PHARMES BELGIË?
PHARMES BELGIË filed 1 annual account with the National Bank of Belgium, for financial year 2025.

Next steps

See how customers, suppliers and banks see your own company and what to improve first.

Keep this company with today's facts in a case file.